Authors of a Lancet study have defended their findings on scheduled birth timing for women at risk of pre-eclampsia. They maintain the intervention can significantly reduce term pre-eclampsia without raising caesarean birth rates or neonatal unit admissions. This reply addresses concerns raised by other researchers regarding the applicability of the trial's results.
The correspondence follows a critique questioning how the original study's clinical setting compares to other contexts. The authors acknowledge this consideration but stand by their core conclusion. They argue personalized timing identifies patients who benefit most from the intervention.